Acrivon Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference WATERTOWN, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based...

Acrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders WATERTOWN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary, proteomics-based technologies driving a new era of...

Acrivon Therapeutics to Present at the Evercore ISI HealthCONx Conference WATERTOWN, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based...

Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline Proceeds to support the clinical development of advanced Phase 2 lead asset ACR-368, a potent DNA Damage Response (DDR) inhibitor clinically validated in solid cancers, and in-house drug pipeline...

Acrivon Therapeutics Launches to Advance Clinical Oncology Pipeline Leveraging its Groundbreaking Precision Proteomics Platform Acrivon signs exclusive worldwide license agreement with Eli Lilly and Company to develop and commercialize prexasertib, a clinically advanced, selective inhibitor targeting DNA Damage Response (DDR)...